中红医疗（SZ 300981，收盘价：13.3元）7月30日晚间发布公告称，公司第四届第十次董事会会议于 2025年7月30日以通讯方式召开。会议审议了《关于公司及子公司与关联方签订屋顶分布式光伏项目能 源管理合同暨关联交易的议案》等文件。 （文章来源：每日经济新闻） 2024年1至12月份，中红医疗的营业收入构成为：医疗器械行业占比100.0%。 ...

Group 1 - Company Zhonghong Medical (300981.SZ) signed an energy management contract for a rooftop distributed photovoltaic project with its affiliate Xiamen Guomao New Energy Technology Co., Ltd. [1] - The project involves providing 25,000 square meters of rooftop space in Tangshan, Hebei for the construction, installation, and operation of a photovoltaic power station [1] - The energy-saving benefit sharing period for the project is set for 25 years, with a rooftop usage period of 20 years, during which Guomao New Energy will pay rent to Zhonghong Medical [1] Group 2 - Subsidiary Jiangxi Kelun Medical Device Manufacturing Co., Ltd. signed a similar energy management contract with its affiliate Jiujiang Luguang Green Energy Co., Ltd. [2] - The project will utilize 13,500 square meters of rooftop space in Yichun, Jiangxi for the construction, installation, and operation of a photovoltaic power station [2] - The energy-saving benefit sharing period is also 25 years, with a rooftop usage period of 20 years, during which Luguang Green Energy will pay rent to Kelun Medical [2]

证券代码：300981 证券简称：中红医疗 公告编号：2025-063 中红普林医疗用品股份有限公司 关于公司及子公司与关联方签订屋顶分布式光伏项目能源 管理合同暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、关联交易概述 （一）基本情况 中红普林医疗用品股份有限公司（以下简称"公司"）于 2025 年 7 月 30 日 召开的第四届董事会第十次会议审议通过《关于公司及子公司与关联方签订屋顶 分布式光伏项目能源管理合同暨关联交易的议案》，为响应"碳中和、碳达峰" 国家战略，贯彻新发展理念，推动清洁能源使用，同时提高资产经济效益，同意 以下事项： 1、公司与关联方厦门国贸新能源科技有限公司（以下简称"国贸新能源"） 签订《屋顶分布式光伏项目能源管理合同》。公司将河北省唐山市滦南经济开发 区城西园区的建筑物 2.5 万平方米的屋顶（具体有效使用面积以双方最终确定的 设计图纸所圈定的红线图面积为准）以及项目电气、输配电设备等所需的安装场 所提供给国贸新能源建设、安装、运营光伏电站项目，国贸新能源按照"合同能 源管理"模式为公司提供专项节能服务。 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司 第四届董事会第十次会议决议公告 一、会议召开情况 中红普林医疗用品股份有限公司（以下简称"公司"）第四届董事会第十次 会议于 2025 年 7 月 30 日以通讯方式召开，2025 年 7 月 25 日公司以电话和电子 邮件方式向全体董事发出会议通知。会议应出席董事 9 人，实际出席董事 9 人。 会议由董事长桑树军先生主持，公司监事、高级管理人员和相关人员列席了会议。 会议的召集、召开符合相关法律、法规和《公司章程》的规定。 二、会议审议情况 1.审议通过《关于公司及子公司与关联方签订屋顶分布式光伏项目能源管 理合同暨关联交易的议案》 董事会认为本项目有利于响应"碳中和、碳达峰"国家战略，贯彻新发展理 念，推动清洁能源使用，同时提高资产经济效益，同意公司及子公司江西科伦医 疗器械制造有限公司分别与公司关联方厦门国贸新能源科技有限公司、九江鹭光 绿色能源有限公司签订《屋顶分布式光伏项目能源管理合同》。 公司独立董事已召开专门会议进行审议并发表一致同意的审核意见。 关联董事桑树军先生、 ...

Group 1 - Changhua Group received a product purchase contract for carbon-ceramic brake discs, with a total sales amount expected to exceed 100 million yuan over a 5-year lifecycle, starting mass production in Q2 2026 [1] - Zhongke Environmental reported a net profit of 196 million yuan for the first half of 2025, a year-on-year increase of 19.83%, with revenue of 848 million yuan, up 4.48% [1] - WuXi AppTec's net profit for the first half of 2025 grew by 101.92% to 8.561 billion yuan, with revenue of 20.799 billion yuan, a 20.64% increase [1][2] - Sujiao Technology's net profit decreased by 39.54% to 95.39 million yuan, with revenue down 13.75% to 1.776 billion yuan [1] - Jucheng Co. reported a net profit of 205 million yuan, a significant increase of 43.5%, with revenue of 575 million yuan, up 11.69% [1] Group 2 - Sanxiang New Materials plans to invest up to 300 million yuan in a zirconium-hafnium separation project, with a production capacity of 20,000 tons [1] - Koweil received government subsidies totaling 4.9752 million yuan, accounting for 10.14% of its audited net profit [1] - Xinhua Medical obtained two Class II medical device registration certificates for digital X-ray machines [1] - Huanxu Electronics reported a net profit of 638 million yuan, down 18.66%, with total revenue of 27.214 billion yuan, a slight decrease of 0.63% [1] - Zhenhua Co.'s general manager was fined 100,000 yuan for violations related to stock trading by his child [1] Group 3 - Huafeng Aluminum signed a raw material purchase contract worth over 7.2 billion yuan for a five-year period, committing to purchase at least 360,000 tons of raw materials [1] - Hongxin Technology received a project designation letter and procurement contract from a major domestic automotive brand [1] - Meihe Co. obtained a patent for a device used in supporting automatic flipping on conveyor lines in the automotive manufacturing sector [1] - Xin Hongye's subsidiary won a bid for an electrical penetration project worth 40.8831 million yuan [1] - Fuan Pharmaceutical's subsidiary received a drug registration certificate for an injection used in liver disease treatment [1] Group 4 - Tianzhong Precision's subsidiary's bankruptcy liquidation application was accepted by the court due to insufficient assets to cover debts [1] - Zhonghong Medical's subsidiary received medical device registration for infusion pumps and information collection systems [1] - Keda Li's subsidiary completed a capital increase, raising its registered capital from 200 million yuan to 400 million yuan [1] - Xingye Technology applied for a credit limit of 372 million yuan from Guangfa Bank [1] - Hengrui Medicine signed a collaboration agreement with GSK, involving a potential total payment of approximately 12 billion USD based on project milestones [1]

Core Viewpoint - Zhonghong Medical (300981) announced that its subsidiary, Shenzhen Maide Ruina Biotechnology Co., Ltd., has recently obtained the Medical Device Registration Certificate issued by the Guangdong Provincial Drug Administration, with a registration category of Class II [1] Group 1 - The registered products include infusion pumps and infusion information collection systems, with the registration certificate valid until July 16, 2030 [1] - The models of the infusion pumps include SP90, SP90Pro, and SP90Neo, while the models of the infusion information collection systems include DS80Pro and DS90Pro [1]

证券代码：300981 证券简称：中红医疗 公告编号：2025-061 中红普林医疗用品股份有限公司 关于子公司深圳迈德瑞纳生物科技有限公司 获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）子公司深圳迈德瑞纳 生物科技有限公司（以下简称"迈德瑞纳"）于近期取得了广东省药品监督管理 局颁发的《中华人民共和国医疗器械注册证》，迈德瑞纳申报的注射泵、输液信 息采集系统医疗器械注册证已审批通过，具体情况如下： | 注册人名称 | 产品名称 | 注册证编号 | 注册分类 | 型号、规 | 注册证有效期至 | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | | | | | | 格 | | | | | | | | | | 与注射器配合使用，用 于静脉输注治疗实现 | | | | | | SP90、SP90 | | 长时间恒定给药速度 | | | | 粤械注准 | | | 2030 年 07 月 16 | 和精确给药量控制，适 | | | 注射泵 | ...

Core Insights - The labor protection products market is experiencing steady growth due to increased national emphasis on safety and occupational health, with a projected market size of 109.93 billion yuan in 2024, reflecting a 1.5% year-on-year increase [1][9][19]. Market Overview - Labor protection products are essential for workers to prevent or mitigate injuries and occupational hazards, categorized into various types such as hand protection, body protection, foot protection, and more [2][4]. - The market is dominated by hand protection and body protection products, with projected market sizes of 39.14 billion yuan and 33.97 billion yuan respectively in 2024, accounting for 35.6% and 30.9% of the total market [11]. Application Areas - The application of labor protection products spans various high-risk industries, including oil and gas, metallurgy, automotive, machinery, and construction, with significant market shares in these sectors: oil, chemical, and natural gas at 14.0%, metallurgy and non-ferrous at 9.6%, automotive at 9.5%, and both machinery and construction at 8.5% [13][19]. Industry Structure - The labor protection products industry in China has developed a complete supply chain covering all categories, with a large number of manufacturers primarily located in Jiangsu, Shandong, and Zhejiang provinces. The industry is characterized by low concentration and a fragmented market structure [17]. - Domestic companies are increasing R&D investments and enhancing product offerings, gaining competitiveness in the mid-to-low-end market, while foreign companies like 3M, DuPont, and Honeywell maintain a strong presence in the high-end segment [17]. Trends and Innovations - The market is expected to grow steadily, with a projected compound annual growth rate (CAGR) of 2.1% from 2024 to 2031, reaching a market size of 127.28 billion yuan by 2031 [19]. - Innovations in materials science and the integration of smart technologies are anticipated to enhance product performance and functionality, with a focus on sustainability through the use of eco-friendly materials [20][21].

证券代码：300981 证券简称：中红医疗 公告编号：2025-060 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 中红普林医疗用品股份有限公司（以下简称"公司"）分别于 2024 年 12 月 9 日、2024 年 12 月 25 日召开第四届董事会第四次会议及第四届监事会第四次会 议、2024 年第三次临时股东大会，审议通过了《关于公司及子公司 2025 年度向 银行申请综合授信额度暨公司为子公司申请综合授信额度提供担保的议案》，同 意公司为控股子公司 2025 年度向金融机构申请的授信额度提供担保，其中，为 资产负债率 70%（含）以上的控股子公司提供担保额度为不超过 15 亿元，为资 产负债率低于 70%的控股子公司提供担保额度为不超过 10 亿元，担保额度总计 不超过 25 亿元。具体内容详见《关于公司及子公司 2025 年度向银行申请综合授 信额度暨公司为子公司申请综合授信额度提供担保的公告》（公告编号：2024- 083）。 二、担保进展情况 近日，为满足公司全资子公司江西中红普林医疗制品有限公司（以下简称"江 西中红"）业 ...

二、对公司的影响及风险提示 上述医疗器械注册证的变更是在原有注册证的基础上根据实际情况及相关 标准进行的相应变更。一次性使用无菌注射器（带针）、一次性使用无菌配药注 射器（带针）领域相关产品的实际销售情况取决于未来市场的推广效果，产品销 售及利润贡献具有不确定性，目前尚无法预测上述产品对公司未来业绩的影响， 敬请相关投资者给予关注并注意投资风险。 证券代码：300981 证券简称：中红医疗 公告编号：2025-059 中红普林医疗用品股份有限公司 关于子公司江西科伦医疗器械制造有限公司完成医疗器械 变更注册的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）子公司江西科伦医疗 器械制造有限公司于近期取得国家药品监督管理局及江西省药品监督管理局颁 发的《医疗器械变更注册（备案）文件》。具体变更情况如下： | 产品名称 | 注册证编号 | 注册分类 | 变更内容 | 备注 | | --- | --- | --- | --- | --- | | 一次性使用无 菌注射器 带针 | 国械注准 20153142006 | ...